Acorn Capital Advisors, LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 17, 2025), Acorn Capital Advisors, LLC reported 20 stock positions worth $197.0 million. Its top holding was CG Oncology (CGON) at 23.1% of the portfolio, followed by Urogen Pharma (URGN, 12.8%) and Puma Biotechnology (PBYI, 11.1%). Compared with Q2 2025, it opened 1 new position, sold out of 2, added to 2 and reduced 1. The biggest buy was a new position in Jasper Therapeutics (JSPR) and the biggest sale an exit from Y-Mabs Therapeutics (YMAB).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002054410
- Portfolio Value
- $197.0M (Q3 2025)
- SEC Filing
- 0001636587-25-000060 ↗ filed Nov 17, 2025
Holdings Value
Holdings 20 stocks · $197.0M
| CGON CG Oncology Inc. | 23.14% | 1,131,501 | $45.6M | No change |
| URGN Urogen Pharma Ltd. | 12.76% | 1,259,749 | $25.1M | No change |
| PBYI Puma Biotechnology Inc. | 11.14% | 4,131,299 | $21.9M | No change |
| TRVI Trevi Therapeutics Inc. | 9.96% | 2,144,844 | $19.6M | No change |
| TERN Terns Pharmaceuticals Inc. | 7.52% | 1,971,264 | $14.8M | No change |
| CADL Candel Therapeutics Inc. | 6.68% | 2,580,517 | $13.2M | No change |
| BCAX Bicara Therapeutics Inc. | 5.16% | 643,382 | $10.2M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 3.96% | 2,839,674 | $7.8M | No change |
| TARA Protara Therapeutic Inc. | 3.87% | 1,752,115 | $7.6M | No change |
| VSTM Verastem Inc. | 3.49% | 779,498 | $6.9M | No change |
| HELP Cybin Inc. | 2.19% | 734,394 | $4.3M | No change |
| CRDF Cardiff Oncology Inc. | 2.05% | 1,962,084 | $4.0M | Add +39.3% |
| AURA Aura Biosciences Inc. | 1.87% | 595,744 | $3.7M | No change |
| BCAB Bioatla Inc. | 1.69% | 4,835,111 | $3.3M | No change |
| JSPR Jasper Therapeutics Inc. | 1.67% | 1,382,640 | $3.3M | New |
| WHWK Whitehawk Therapeutics Inc. | 1.10% | 1,139,363 | $2.2M | No change |
| QTTB Q32 Bio Inc. | 0.81% | 803,425 | $1.6M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.47% | 273,349 | $935K | Add +77.8% |
| ACRV Acrivon Therapeutics Inc. | 0.37% | 405,237 | $733K | No change |
| VYNE THERAPEUTICS INC | 0.10% | 586,572 | $199K | Reduce -20.4% |
Portfolio Sells Q2 2025 → Q3 2025
| YMAB Y-Mabs Therapeutics Inc. | Sold out | 0.00% | −10.09 |
| MURA Mural Oncology PLC | Sold out | 0.00% | −1.06 |
| VYNE THERAPEUTICS INC | Reduce -20.4% | 0.10% | −0.69 |
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $366.5M | CGON, URGN, TRVI, CADL, PBYI |
| Q1 2026 | 22 | $351.8M | TERN, CGON, URGN, PBYI, TRVI |
| Q4 2025 | 21 | $295.1M | TERN, CGON, URGN, TRVI, PBYI |
| Q3 2025 | 20 | $197.0M | CGON, URGN, PBYI, TRVI, TERN |
| Q2 2025 | 21 | $152.9M | CGON, URGN, YMAB, PBYI, CADL |
| Q1 2025Amended | 22 | $149.9M | CGON, URGN, YMAB, TRVI, CADL |
| Q4 2024Amended | 21 | $185.8M | CGON, YMAB, CADL, URGN, PBYI |